Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Translational Therapeutics

RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function

British Journal of Cancer (2024)Cite this article

Subjects

Dear Dr. Evans,

I read the article titled “Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells,” published by Rio-Vilariño and colleagues [1] in the last issue of the British Journal of Cancer. While the title is enticing, the interpretation of the study could be spurious. The authors interpret that YAP1 Ser 397 phosphorylation activates YAP; however, this assertion is not correct. The Hippo signalling pathway negatively regulates the transcriptional coactivator YAP1 through LATS-mediated phosphorylation at two sites: Ser 127 and Ser 397, which drive YAP inactivation. LATS phosphorylation at serine 127 promotes YAP1 cytoplasmic retention, while phosphorylation at serine 397 creates a phosphodegron that signals for β-TrCP-driven E3 ligase-mediated degradation [2]. To confirm YAP1 activation, it is important to assess the expression of downstream representative genes such as CYR61. I recommend that the authors revisit their findings and carefully reinterpret them.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez P, Schlaepfer MI, Del Puerto-Nevado L, et al. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. Br J Cancer. 2024;130:1402–13.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287–312.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IOR, Dr. Rosell Oncology Institute, Dexeus University Hospital, 08028, Barcelona, Spain

    Rafael Rosell

Authors
  1. Rafael Rosell
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualisation, Writing original draft, review & editing: RR.

Corresponding author

Correspondence to Rafael Rosell.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosell, R. RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02720-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41416-024-02720-9

Search

Advanced search

Quick links